MedTrace Logo

Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG

NCT07192211 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-09-25

No results posted yet for this study

Summary

ADR-002K is administered to heart failure patients with ischemic heart disease who undergo coronary artery bypass surgery (CABG) to investigate its efficacy and safety.

Conditions

  • Ischemic Heart Disease

Interventions

BIOLOGICAL

Mesenchymal stem cell

ADR-002K administration

BIOLOGICAL

Placebo

Placebo

Sponsors & Collaborators

  • Rohto Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Shigeru Miyagawa, profesor · Osaka University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2028-09-30
Completion
2029-03-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07192211 on ClinicalTrials.gov